Casgevy sickle cell gene therapy is now FDA-approved for children as young as two, opening access for 5,500 more U.S. kids.

The rise of AI in drug development is just beginning its journey to delivering treatments to patients.

Anthropic also went a step further, saying it would develop drugs of its own. Head of life sciences Eric Kauderer-Abrams said ...

AI-driven drug discovery, using LLMs and diffusion models, has improved drug design and reduced timelines. Although promising ...

The mid-stage disappointment in Alzheimer’s disease delivers another blow to Neuphoria Therapeutics, which in November last year was forced to launch a strategic business review after a Phase 3 trial ...

ALP Bio is developing an AI-powered platform that helps drug developers identify immune-related risks earlier in the ...

A man who sold land for a controversial, Jared Kushner-backed luxury development in Albania is suspected of money laundering ...

Artificial intelligence (AI) is quickly becoming a key factor for life sciences companies. In addition to improving efficiency and ...

MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, and Bora Pharmaceuticals Co., Ltd ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...

AI is transforming medicine development by accelerating drug discovery and clinical trials, reducing costs, and enhancing the efficiency of pharmaceutical processes.

As radiopharmaceutical therapy (RPT) expands beyond neuroendocrine tumors and prostate cancer, it is important to understand ...